1615 related articles for article (PubMed ID: 19270277)
1. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
3. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
5. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
6. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
7. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
8. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
9. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Ansari NA; Jain RK; Salotra P
Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
[No Abstract] [Full Text] [Related]
10. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L
Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365
[TBL] [Abstract][Full Text] [Related]
12. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
13. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
14. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311
[TBL] [Abstract][Full Text] [Related]
15. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
Ramesh V; Avishek K; Sharma V; Salotra P
Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Sundar S; Singh A; Chakravarty J; Rai M
ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
